Drugs / phosphatidylcholine
phosphatidylcholine
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01905605 | Sep 2013 → Jan 2017 | schizophrenia | University of Colorado, Denver | Withdrawn | No outcome recorded Stop: Business |
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT01011322 | Dec 2009 → Jul 2011 | diarrheal disease, ulcerative colitis | Lipid Therapeutics GmbH | Unknown | Met primary |
| Phase 2 | NCT00259558 | Apr 2003 → Mar 2006 | ulcerative colitis | Heidelberg University | Completed | No outcome recorded |
| Phase 2 | NCT00259545 | Feb 2003 → Feb 2006 | ulcerative colitis | Heidelberg University | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00259571 | ? → Mar 2010 | ulcerative colitis | Heidelberg University | Withdrawn | No outcome recorded Stop: Business |
| Phase 33 trials · 2 missed | ||||||
| Phase 3 | NCT02517385 | Aug 2015 → Jun 2016 | hepatobiliary disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02280629 | Oct 2014 → Oct 2018 | ulcerative colitis | Dr. Falk Pharma GmbH | Completed | Missed primary |
| Phase 3 | NCT02142725 | Jul 2014 → Nov 2016 | ulcerative colitis | Dr. Falk Pharma GmbH | Terminated | Missed primary |
| Phase not applicable2 trials · 1 met primary | ||||||
| — | NCT00757081 | Jun 2008 → Dec 2009 | — | BodyAesthetic Research Center | Completed | Met primary |
| — | NCT00006061 | Jan 2000 | methionine adenosyltransferase deficiency | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02878863 Background | Aug 2016 → Mar 2017 | autoimmune hepatitis | Xiaoli Fan | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Phosphatidylcholine | “The primary objective is to evaluate the efficacy of LT-02, a newly designed modified release phosphatidylcholine formula, in a multicenter setting.” PMID 24796768 ↗ May 20149“LT-02, a novel modified-release phosphatidylcholine (PC) formulation” PMID 37806372 ↗ Oct 2023 |
| Known as | ESSENTIALE paste | “Phosphatidylcholine paste 600 mg (ESSENTIALE® paste) oral 3 times a day for 12 weeks” NCT02517385 ↗ |
| Known as | LT-02 | “The primary objective is to evaluate the efficacy of LT-02, a newly designed modified release phosphatidylcholine formula, in a multicenter setting.” PMID 24796768 ↗ May 20141“Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials.” PMID 37806372 ↗ Oct 2023 |
| Known as | rPC | “BACKGROUND: In 2 preceding studies, delayed release phosphatidylcholine (rPC) was found to (a) improve disease activity and (b) withdraw steroids in patients with...” PMID 20048683 ↗ May 2010 |
| Modality | Other / unclassified | “a novel modified-release phosphatidylcholine (PC) formulation” PMID 37806372 ↗ Oct 2023 |
| Route | Oral | “receives oral phosphatidylcholine supplement” NCT00006061 ↗ |